Patient
SITE001-0165
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE001 (USA) (Dr. Reyes)
consented 2026-03-17
Adverse events
8
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 8
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-10-04 (study day 9); relationship: not assessed
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-02 (study day 7); relationship: not assessed; serious criteria: life-threatening
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-02 (study day 7); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-01 (study day 6); relationship: not assessed
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-09-29 (study day 4); relationship: RELATED
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-09-29 (study day 4); relationship: NOT RELATED
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-27 (study day 2); relationship: NOT RELATED
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-09-27 (study day 2); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.